National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Acute lymphoblastic leukemia (ALL) represent about 77% of leukemia in children and it is one of the most common malignancies in children. Bone Sialoprotein-1 is a tumor –associated antigen that is highly expressed in many malignancies in human. This study was aimed to study the role of Bone Sialoprotein-1 and its receptors CD44 variant 6 in children’s with acute lymphoblastic Leukemia in Tanta University Hospital. This study was carried out in hematology unit, pediatric department and clinical pathology department, Tanta university hospital, Egypt. 40 children patients were included in this study and 10 healthy controls. The serum levels of Bone Sialoprotein-1 were measured in both healthy control and ALL children patients by ELISA and CD44 variant 6 by flowcytometry. Bone Sialoprotein-1 levels in patient group was 112.69 ± 11.54 ng/mL which was significantly higher than that of control group 8.58 ± 2.19 ng/mL (P value was 0.001), CD44 variant 6 level in patient group was 32.18 ± 15.26 which was significantly higher than that of control group 3.54 ± 1.40 (P value was 0.001) and there was significant difference between level of both Bone Sialoprotein-1 and CD44 variant 6 in cases of good and bad prognosis (P value was0.001). As regard comparison between level of CD44 variant 6 and level of BSP-1 in cases of bad prognosis 22 (55%) of cases were positive for both BSP-1 and CD44 variant 6 and of bad prognosis (P value was 0.002). BSP-1 level and CD44v6 expression in childhood ALL patients may be used as prognostic markers to predict outcome as it has a tendency to be high with cases of bad prognosis.
Citations |
 |
 |
 |
 |
